<SEC-DOCUMENT>0001493152-20-021823.txt : 20201117
<SEC-HEADER>0001493152-20-021823.hdr.sgml : 20201117
<ACCEPTANCE-DATETIME>20201117073035
ACCESSION NUMBER:		0001493152-20-021823
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201117
DATE AS OF CHANGE:		20201117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HARROW HEALTH, INC.
		CENTRAL INDEX KEY:			0001360214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450567010
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35814
		FILM NUMBER:		201319261

	BUSINESS ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215
		BUSINESS PHONE:		615.733.4731

	MAIL ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Imprimis Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20120301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSDEL PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20070912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bywater Resources, Inc
		DATE OF NAME CHANGE:	20060421
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:HROW="http://harrowinc.com/20201109">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_HROW_harrowinc.com_20201109 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20201108_20201109 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001360214 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:EntityCentralIndexKey">0001360214</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="hrow-20201109.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-11-08to2020-11-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-08</xbrli:startDate>
        <xbrli:endDate>2020-11-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_908_edei--DocumentType_c20201108__20201109_zppGAbg5Skrb"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date
of Report (Date of earliest event reported): <span id="xdx_902_edei--DocumentPeriodEndDate_c20201108__20201109_zhmBOXaHH36e"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 9, 2020</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityRegistrantName_c20201108__20201109_zpbdNROc5yVh"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:EntityRegistrantName">HARROW
HEALTH, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20201108__20201109_zbywIJi9QCn"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityFileNumber_c20201108__20201109_zNj3fsiHAXYj"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:EntityFileNumber">001-35814</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20201108__20201109_zUGnPbYWbwU4"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:EntityTaxIdentificationNumber">45-0567010</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State
                                         or other jurisdiction</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">of
        incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Commission</span></p>
                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">File
                                         Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(IRS
                                         Employer</span></p>
                                                                             <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Identification
                                         No.)</span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20201108__20201109_zu84zYxppwO8"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:EntityAddressAddressLine1">102
    Woodmont Blvd.</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20201108__20201109_z9c8ycgamKR8"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:EntityAddressAddressLine2">Suite 610</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20201108__20201109_zdgS2kbZPgT1"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:EntityAddressCityOrTown">Nashville</ix:nonNumeric></span>,
    <span id="xdx_906_edei--EntityAddressStateOrProvince_c20201108__20201109_zKoa9AK4JiDi"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Tennessee</ix:nonNumeric> </span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20201108__20201109_zzmTro4mwgDh"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:EntityAddressPostalZipCode">37205</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip
    Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Registrant&#8217;s
telephone number, including area code: <span id="xdx_90B_edei--CityAreaCode_c20201108__20201109_zSh47Pzijcl4"><b><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:CityAreaCode">(615)</ix:nonNumeric></b></span></span><b>
<span id="xdx_90E_edei--LocalPhoneNumber_c20201108__20201109_z7yZrwv8PjA9" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:LocalPhoneNumber">733-4730</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityInformationFormerLegalOrRegisteredName_c20201108__20201109_zWQYdOOkXbLe"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:EntityInformationFormerLegalOrRegisteredName">Not
Applicable</ix:nonNumeric></span></b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Former Name or Former
Address, if Changed Since Last Report)</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name
    on exchange on which registered</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--Security12bTitle_c20201108__20201109_zgt56aWxmWOc"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--TradingSymbol_c20201108__20201109_zWPsn6FqAjJ6"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" name="dei:TradingSymbol">HROW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
    <span id="xdx_904_edei--SecurityExchangeName_c20201108__20201109_zD99kaJACllj"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Global Market</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--WrittenCommunications_c20201108__20201109_zkAX02rtHZGi"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--SolicitingMaterial_c20201108__20201109_zGtQQIKIyRXj"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20201108__20201109_ziJfzEqGrpZ6"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20201108__20201109_zCy6rWHKu0aa"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Act of 1934: Emerging growth company <span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20201108__20201109_zGU3OVpPFMLk"><ix:nonNumeric contextRef="From2020-11-08to2020-11-09" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
any emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 33%">&#160;</td><td style="text-align: center; width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
2.02 Results of Operations and Financial Condition.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 9, 2020, Harrow Health, Inc. (the &#8220;Company&#8221;) issued a press release and a letter to stockholders announcing
its financial results for the period ended September 30, 2020 and an update on recent corporate events. The press release and
letter to stockholders are being furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information furnished under this Item 2.02 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be
deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;), or otherwise subject to the liabilities of that Section. The information in this Item 2.02, including Exhibits 99.1
and 99.2, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except to the extent it is specifically incorporated by reference but regardless of any general incorporation language in
such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information furnished under this Item 2.02 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be
deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that
such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does
not assume any obligation to update such information or exhibit in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
9.01. Financial Statements and Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>(d)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibits</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Press Release issued by Harrow Health, Inc. on November 9, 2020</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ex99-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Letter to Stockholders by Harrow Health, Inc. dated November 9, 2020</span></a></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 33%">&#160;</td><td style="text-align: center; width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18.35pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>HARROW HEALTH, INC.</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Dated:
    November 9, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Andrew R. Boll</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Andrew
    R. Boll</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 256.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 256.5pt"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 33%">&#160;</td><td style="text-align: center; width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 256.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2WUwlIXxMKiILkYhet5xiSXdkdrX8pP6yTYmGgWHmzrlXCF9saK1qZDgvyxyO2LS1tAgl3pBRX9F9ZNtdCm6WeFfGstR2XH9gRo5BxyRBcnH38bNXBqsUomgWLmZxCFGcJnMo9sL76hnpm6pQWyVrkLqCgqllhVbyMDkc5Ys0NcOYdEI2irSzC8JJfkMcRjEcqJdP4oeBPM+E54/liQ1T135jOmOpgVWNjcsyE/pv7wPeRkka -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 89; width: 250"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Harrow
Health Publishes Third Quarter 2020 <I>Letter to Stockholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.1pt">Nashville,
TN &ndash; November 9</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, 2020 &ndash; Harrow Health,
Inc. (NASDAQ: HROW) today reported results for the third quarter 2020. Please <U>click here</U> to review Harrow Health&rsquo;s
<I>Letter to Stockholders </I>for the third quarter 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
L. Baum, CEO of Harrow Health, commented, &ldquo;The third quarter of 2020 was the best financial quarter in the history of the
Company. Our team delivered on revenues, gross margins, and nearly every other internal financial metric that we chart. Revenues
in July were better than June; and each subsequent month continued to improve, resulting in a company record revenues, gross margins
and adjusted EBITDA. As we move into the fourth quarter and set our sights on 2021, we are hopeful our revenue trend, which currently
looks V-shaped, will quickly transition into a <I>checkmark-shaped</I> trend line into 2021. In addition to the outstanding performance
of ImprimisRx, other Harrow businesses continued to hit new and major milestones, and we expect to see more value inflection events
in the coming quarterly periods.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conference
Call and Webcast</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company&rsquo;s management team will host a question and answer conference call with analysts and an audio-only webcast today
at 4:45 p.m. Eastern Standard Time / 1:45 p.m. Pacific Standard Time. To participate, please use the dial in or
click on the link below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>U.S.
    callers</U>: (844) 602-0380</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>International
    callers</U>: (862) 298-0970</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Audio-only
    webcast</U>: please <U>click here</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conference
Call Replay</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
dial in replay of the call will be available until December 09, 2020. <FONT STYLE="background-color: white">The webcast replay
will be available until February 09, 2021.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>U.S.
    callers</U>: (877) 481-4010, <FONT STYLE="background-color: white">Replay ID: 38433</FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>International
    callers</U>: <FONT STYLE="background-color: white">(919) 882-2331, Replay ID: 38433</FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Webcast</U>:
    please <U>click here</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Harrow Health</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including <U>ImprimisRx</U>, the nation&rsquo;s leading
ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in <U>Eton
Pharmaceuticals</U>, <U>Surface Ophthalmics</U>, and <U>Melt Pharmaceuticals</U>. Harrow also owns Mayfield Pharmaceuticals, Stowe
Pharmaceuticals, and Visionology, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights
in certain drug candidates being developed by Surface, Melt, and Mayfield. Harrow intends to create, invest in and grow paradigm
shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations
section of the corporate website by <U>clicking here</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be considered such &ldquo;forward-looking statements.&rdquo;
Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties which
may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties
that could cause actual results to differ from those predicted include our ability to make commercially available our compounded
formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related
to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies,
physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual
property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds
when necessary; risks related to research and development activities; the projected size of the potential market for our technologies
and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies,
outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties
are more fully described in Harrow Health&rsquo;s filings with the Securities and Exchange Commission, including its Annual Report
on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC&rsquo;s web site at
<U>www.sec.gov</U>. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are
made. Except as required by law, Harrow Health undertakes no obligation to update any forward-looking statements to reflect new
information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ir@harrowinc.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
Harrow Health, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Harrow
Health, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Letter
to Stockholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
9, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Stockholders of Harrow Health, Inc.:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third quarter of 2020 was the best financial quarter in the history of the Company. Our team delivered on revenues, gross margins,
and nearly every other internal metric that we chart. Revenues in July were better than June; and each subsequent month continued
to improve. We were also pleased that while we achieved Q3 record revenues, we also hit an Adjusted EBITDA record, an important
correlative trend we expect to continue as revenues grow. Finally, from a financial perspective, we expect that an increasing
percentage of each incremental dollar of additive revenue will improve our Adjusted EBITDA figure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we move into the fourth quarter and set our sights on 2021, we are hopeful our revenue trend, which currently looks V-shaped,
will quickly transition into a &ldquo;checkmark-shaped&rdquo; trend line into 2021. We believe this trend of growth will be driven
by expanding our core business through new customer growth, continuing to expand within the many thousands of accounts we currently
serve, launching new products in our development pipeline, and adding new revenue sources - such as Dexycu&reg; commissions and
those from other strategic initiatives we&rsquo;ve been working on.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the record performance of ImprimisRx, as discussed below, other Harrow businesses continued to hit new and major milestones,
and we expect to see more value inflection events in the coming quarterly periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lastly,
once we complete the deconsolidation of Mayfield Pharmaceuticals, we intend to leverage our position in eyecare and from a strategic
perspective, exclusively focus on investing in and developing eyecare-related healthcare goods and services. We believe that Harrow&rsquo;s
focus on eyecare will better serve our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Consolidated
Financial Highlights</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
revenues were $14.4 million for the third quarter of 2020, compared to $12.8 million for the same period last year, and up nearly
80% from second quarter of 2020, when we recorded $8.1 million in revenues. Based on the revenues we recorded in the month of
October, we expect that our revenue trend will be stable into the fourth quarter and grow further in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
margins rapidly rebounded in the third quarter of 2020, up to a new high of 74%, compared to 68% in the third quarter of 2019,
and 60% in the second quarter of 2020. This increase in gross margins was primarily related to the increase in unit volumes sold,
increased production efficiencies and capacity utilization during the period. Adjusted EBITDA for the third quarter of 2020 was
$3.0 million compared to $1.5 million in the third quarter of 2019. A reconciliation of all non-GAAP financial results in this
letter appears beginning on page 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 7</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
income during the third quarter of 2020 was $1.6 million, compared to an operating loss of $4.4 million during the same period
last year. We recorded a non-cash gain related to our Eton Pharmaceuticals ownership position of $8.6 million, which pushed other
income to $7.0 million and resulted in net income attributable to Harrow Health, Inc. of $8.6 million during the third quarter
of 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
additional metric we track is the ImprimisRx segment contribution. In the third quarter of 2020, segment contribution from ImprimisRx
was $4.7 million, which includes non-cash expenses related to depreciation, amortization and stock-based compensation of $528,000.
This important metric demonstrates the earnings power of the ImprimisRx business separately from other Harrow businesses, assets
and liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected
highlights regarding operating results for the three and nine months ended September 30, 2020 and for the same periods in 2019
are as follows (in thousands, except per share data):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left">Total Revenues</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">14,399</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">12,755</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cost of Sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,696</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,061</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Gross Profit</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">10,703</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">8,694</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Selling, General &amp; Administrative Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,436</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,608</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research &amp; Development Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(670</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(444</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Impairment of Intangible Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,040</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Total Operating Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,106</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,092</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Operating Income (Loss)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,597</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(4,398</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other Income (Expense), net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,232</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Net Income (Loss)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">8,623</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(11,630</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net Loss attributable to noncontrolling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net Income (Loss) attributable to Harrow Health, Inc.</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">8,638</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(11,469</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Income (Loss) per share of common stock, basic</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">0.33</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.45</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net Income (Loss) per share of common stock, diluted</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">0.32</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.45</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Nine Months Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left">Total Revenues</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">34,276</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">38,561</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Cost of Sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,526</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,184</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Gross Profit</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">23,750</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">25,377</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Selling, General &amp; Administrative Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,806</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,399</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research &amp; Development Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,822</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,659</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Impairment of Intangible Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(363</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,040</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Total Operating Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,991</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,098</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Operating Loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(2,241</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(5,721</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other (Expense) Income, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,319</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,004</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; text-align: left">Net Loss</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(4,560</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(2,717</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net Loss attributable to noncontrolling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">228</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net Loss attributable to Harrow Health, Inc.</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(4,506</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(2,489</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Loss per share of common stock, basic and diluted</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.17</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.10</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 7</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>ImprimisRx,
a wholly owned subsidiary founded in 2014</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ImprimisRx
is an ophthalmic-focused pharmaceutical company with capabilities that include formulation development, scalable production, quality
systems required by the highest federal manufacturing standards, U.S. and state-specific licensure to dispense direct-to-prescriber/institution
or direct-to-patient, and a national commercial team that sells to and services prescribers, institutions, and patients in all
50 states<I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third quarter was the most successful operational quarter in the history of ImprimisRx. New pharmaceutical production automation
equipment came online, the team successfully launched new software systems to enhance customer experience and create additional
visibility into the business, and our quality systems continued to improve. However, my favorite statistic is our Net Promoter
Score &ndash; which is a measure of our customers&rsquo; willingness to recommend our business to others. After conducting over
4,000 customer surveys during the third quarter of 2020, our NPS has remained steady at 92 &ndash; <I>an incredible achievement</I>.
This score shows the affinity between ImprimisRx and its customers &ndash; <I>which is a key directional indicator of the true
value of the business</I>. We also saw net revenue per 503B order increase to $1,900 per order in the third quarter of 2020 compared
to $1,770 per order in the third quarter of 2019. ImprimisRx&rsquo;s President, John Saharek, and the ImprimisRx team, deserve
great credit for this success. I am convinced that the ImprimisRx business can and will continue to improve and deliver more value
to our customers, driving meaningful financial value to Harrow stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Late
last year, we began a process to leverage the ImprimisRx platform to add new FDA-approved and soon-to-be-FDA-approved ophthalmic
products to the ImprimisRx platform. Our agreement with EyePoint Pharmaceuticals (NASDAQ: EYPT) to sell Dexycu&reg; was the first
achievement in the execution of this strategy. However, we have several other revenue-expanding deals in the pipeline and our
team is looking forward to making announcements on these new initiatives in the near term. The ImprimisRx commercial team has
successfully initiated new customer trials of Dexycu&reg; with some of its largest Tri-Moxi customers, and this success has led
to an early expansion of the EyePoint agreement to accelerate our outreach in terms of the number of ImprimisRx customers
we&rsquo;re able to bring the exciting Dexycu&reg; offering to.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, our efforts to leverage the ImprimisRx platform are underway. We continue to believe ImprimisRx is at the start of a
growth run that we expect to last for many years, leading to ImprimisRx achieving our goal of becoming one of the largest ophthalmic
pharmaceutical companies in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 7</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Deconsolidated
Companies and Subsidiaries</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deconsolidated
Companies (Non-Controlled Investments)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Eton
    Pharmaceuticals</U> (NASDAQ: ETON), founded by Harrow in 2017, delivered with two recent FDA approvals, EM-100 ($600 million
    potential addressable market) and Alkindi&reg; Sprinkle (an Orphan Drug Designated product with a $100 million potential addressable
    market). Eton was recently assigned a May 2021 PDUFA date for its Orphan Drug Designated dehydrated alcohol program, which
    Eton estimates is a greater than $100 million market with one competitor, and another May 2021 PDUFA action date for its zonisamide
    oral suspension. In October 2020, Eton submitted a New Drug Application (or NDA) for its third neurology product candidate,
    ET-101 (topiramate oral solution), while completing a $22.5 million &ldquo;above-market price&rdquo; capital raise to help
    fund the launch of these exciting products and product candidates. Harrow maintains a 3,500,000 common share position in Eton
    representing approximately 15% of the outstanding equity of Eton.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Surface
    Ophthalmics (formerly Surface Pharmaceuticals)</U>, founded by Harrow in 2017, continues to make clinical progress in its
    ocular surface disease programs, with three active INDs on file. Phase 2 data on SURF-201 is expected in the next couple of
    months. In addition, SURF-100 is expected to generate Phase 2 data within the next 12 months and the SURF-200 clinical development
    program is underway. We believe that Surface is well positioned to seek and complete a Series B funding in the first part
    of 2021. Harrow holds approximately 30% of the equity interests in Surface along with royalty rights on all drug candidates
    Surface is developing.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Melt
    Pharmaceuticals</U>, founded by Harrow in 2018, began enrolling patients in its Phase 1 study during the third quarter of
    2020. Melt management has indicated that it hopes to have topline data available from this study in the coming months. Here
    is a <U>link</U> to a video that depicts the promise of Melt&rsquo;s pharmaceutical drug candidates, if FDA-approved. We continue
    to expect Melt to complete a Series B financing within the next six months. Harrow holds approximately 44% of the common stock
    in Melt along with royalty rights on all drug candidates Melt is currently developing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiary
Companies (Controlling Interests)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Visionology
    </U>has begun the process of pitching to potential investment partners and we hope to announce the closing of its Series A
    financing within the next few months. While telemedicine is a &ldquo;hot&rdquo; space, we believe that Visionology is much
    more than telemedicine, and therefore is a much more interesting business. Visionology takes advantage of everything we know
    about ophthalmology and eyecare along with the expertise of Drew Livingston, the co-founder and former CEO of Doxy.me, the
    world&rsquo;s largest and fastest growing SaaS-based telemedicine business. I look forward to sharing more about how we expect
    Visionology to change the game for chronic eyecare health management, and how Visionology will help drive what we believe
    is the coming revolution in patient-driven healthcare access and transparency.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 7</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    behalf of <U>Stowe Pharmaceuticals</U>, Harrow recently completed in vitro and in vivo studies on STE-006 (formerly known
    as MUL-1867) and a second Harrow-owned topical formulation (DS-007), at a leading U.S. academic research institution which
    focuses on ocular-specific investigations. The objective of these studies was to determine whether the active test articles
    had in vitro killing power against relevant ophthalmic isolates of bacteria, viruses, and fungi; in vivo killing power against
    adenovirus-5; and if they were tolerable as surface-acting agents using the Draize scale. Past anti-bacterial data for STE-006
    was strong; and while our initial read on anti-viral data from these studies was positive, we were not able to replicate prior
    data conducted on STE-006. Therefore, while we remain keenly interested in pathogen-agnostic topical agents to treat non-specific
    conjunctivitis (such as DS-007), we do not intend to invest further in STE-006. We intend to update our stockholders on further
    progress with DS-007 and other Harrow formulations in the anti-infective category in the coming quarters.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mayfield
    Pharmaceuticals</U> is continuing to advance its drug pipeline and programs. We expect to have more to discuss about Mayfield
    at the time of our next quarterly stockholder update.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Financial
Outlook</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are pleased with the strength of our underlying eyecare businesses and the momentum we have established with our customers and
business partners. Importantly, during the third quarter, our business produced $2.6 million of cash from operations, helping
push our cash balance to a level we have not seen since December 31, 2018. We do not believe the third quarter revenues and financial
performance were a fluke and expect revenues and our cash balance to grow throughout next year. We continue to remain highly optimistic
about the prospects of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
though we have hit our previous target of 70% gross margins, we are pressing the team to continue to find new efficiencies that
can drive gross margins higher. As we start to see more contribution from sales of Dexycu&reg; to our topline, there should be
a corresponding expansion of our gross and operating margins even further in the near term. ImprimisRx is a powerful pharmaceutical
platform that in the third quarter demonstrated the earnings capability of incremental revenue growth in the business. As we execute
on our operational plan, we will continue to build upon our strategic objectives, including inorganic growth opportunities and
enhancing the profitability profile of the business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Closing</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
want to thank the employees of Harrow, ImprimisRx, and every Harrow-connected business for delivering exceptional results. Business
is good, and we believe it will continue to get even better. Our pipeline of deal-flow is strong, and we are working on transactions
that are potentially transformative. I am confident that the work we are doing to bring in new ophthalmic products and other opportunities
will change the profile of our company in a positive way. Much work is left to do. We look forward to reporting on continued execution
and action in the next <I>Letter to Stockholders</I> in March of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
L. Baum</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder
and Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nashville,
Tennessee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 7</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s remarks in this stockholder letter include forward-looking statements within the meaning of federal securities
laws. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Harrow Health&rsquo;s
control, including risks and uncertainties described from time to time in its SEC filings, such as the risks and uncertainties
related to the Company&rsquo;s ability to make commercially available its compounded formulations and technologies, and FDA approval
of certain drug candidates in a timely manner or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a list and description of those risks and uncertainties, please see the &ldquo;Risk Factors&rdquo; section of the Company&rsquo;s
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
Health&rsquo;s results may differ materially from those projected. Harrow disclaims any intention or obligation to update or revise
any financial projections or forward-looking statements whether because of new information, future events or otherwise. This stockholder
letter contains time- sensitive information and is accurate only as of today.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
Harrow Health refers to non-GAAP financial metrics, specifically Adjusted EBITDA and/or adjusted earnings. A reconciliation of
any non-GAAP measures with the most directly comparable GAAP measures is included in this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
ImprimisRx compounded formulation is FDA-approved. All ImprimisRx formulations are customizable. Other than drugs compounded at
a registered outsourcing facility, all ImprimisRx compounded formulations require a prescription for an individually identified
patient consistent with federal and state laws.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>All
trademarks, service marks and trade names included or referenced in this publication are the property of their respective owners.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Adjusted
EBITDA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Company&rsquo;s results of operations determined in accordance with U.S. generally accepted accounting principles
(GAAP), which are presented and discussed above, management also utilizes Adjusted EBITDA, an unaudited financial measure that
is not calculated in accordance with GAAP, to evaluate the Company&rsquo;s financial results and performance and to plan and forecast
future periods. Adjusted EBITDA is considered a &ldquo;non-GAAP&rdquo; financial measure within the meaning of Regulation G promulgated
by the SEC. Management believes that this non-GAAP financial measure reflects an additional way of viewing aspects of the Company&rsquo;s
operations that, when viewed with GAAP results, provides a more complete understanding of the Company&rsquo;s results of operations
and the factors and trends affecting its business. Management believes Adjusted EBITDA provides meaningful supplemental information
regarding the Company&rsquo;s performance because (i) it allows for greater transparency with respect to key metrics used by management
in its financial and operational decision-making; (ii) it excludes the impact of non-cash or, when specified, non-recurring items
that are not directly attributable to the Company&rsquo;s core operating performance and that may obscure trends in the Company&rsquo;s
core operating performance; and (iii) it is used by institutional investors and the analyst community to help analyze the Company&rsquo;s
results. However, Adjusted EBITDA and any other non-GAAP financial measures should be considered as a supplement to, and not as
a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures
used by the Company and the manner in which they are calculated may differ from the non-GAAP financial measures or the calculations
of the same non-GAAP financial measures used by other companies, including the Company&rsquo;s competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 7</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company defines Adjusted EBITDA as net income (loss) excluding the effects of interest, taxes, depreciation, amortization, stock-based
compensation, other income (expense)<B>, </B>investment (gains)/ losses, net and, if any and when specified, other non-recurring
income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net
income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net income (loss)
as a measure of operating performance or to net cash provided by (used in) operating, investing or financing activities as a measure
of ability to meet cash needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net income (loss),
for the three months ended September 30, 2020 and for the same period in 2019 (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended September 30,&nbsp;2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Three Months Ended September 30,&nbsp;2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%; font-weight: bold; text-align: left">GAAP Net Income (Loss)</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 21%; font-weight: bold; text-align: right">8,638</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 21%; font-weight: bold; text-align: right">(11,469</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock-based compensation and payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">403</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">498</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">620</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">464</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Investment (gains)/losses, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,519</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-recurring expenses <SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Adjusted EBITDA</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">3,032</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,460</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&nbsp;</SUP></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-right: auto; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; text-align: left; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>&nbsp;(1)
</SUP>2019 non-recurring expenses includes costs accrued in connection with litigation settlements, impairment of long-lived assets
and wind-down costs (including severance) associated with the restructuring of our Irvine, California pharmacy business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Equity
Portfolio</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Company</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares of Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Estimated Value at</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 30, 2020</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Eton Pharmaceuticals</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">3,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">27,650,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Surface Ophthalmics</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,550,0001</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Melt Pharmaceuticals</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">3,500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,500,0001</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; font-weight: bold; text-align: left">Estimated Total Value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">56,700,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-right: auto; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; text-align: left; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><SUP>1
</SUP>Represents a non-GAAP value, which is calculated as the conversion price of the Series A Preferred Stock (from the most
recent offering of the applicable company) multiplied by the number of shares owned by Harrow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: right; width: 100%">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 7</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #L E<# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$'_8-N/_ $6U8+<Z9;'Q]7J?P$_Y'J]_[!LG_HR*O+*]3^ G_(]7O_8-D_\
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M?^ADUC_P.E_^*J2'QKXJ@FCE3Q'JI9&# /=NZDCU4D@CV-=I_P *%\4_\_\
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M*F13W50"??G .1C-=5HP1R7E-G"XKK?#_P 2?%7AV1?L^IR7-NH"_9KPF6/
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M]@VX_P#1;5@MSIEL?'U>I_ 3_D>KW_L&R?\ HR*O+*]3^ G_ "/5[_V#9/\
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M?\S'_P!NW_M6O$:]N_9ZZ^(_^W;_ -JUV5O@9QT?C1[?7#_%W_DEVL?]L/\
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M)()XVBD0\!E88(_*OCK6=*FT36[W2[C/FVDS1%BI7=@\, >Q'(]C7V=7SO\
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M0?\ 8-N/_1;5NUA>-/\ D1O$'_8-N/\ T6U);CEL?'U>I_ 3_D>KW_L&R?\
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M !=+_P +3UW_ )]M/_[]O_\ %U*H5$6\33:LRG_PSXG_ $,K?^ 7_P!LKLO
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M[CN+<K@>A<,?_0:T_P#A:>N_\^NG_P#?M_\ XNC_ (6IKO\ SZZ?_P!^W_\
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M90_X9Z_ZF?\ \I__ -LKTSP5X6A\'>'(M)BF$[J[R2SB/9YK$]2,GHNU>O\
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M*>IS5*\VM#M]1UG4=5???7LT_P VX*[?*I]EZ#\*HT45U));'$VWN=-\/_\
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M\([KG_0&U#_P%?\ PKV3Q;XA?PUI<5XELLY>81;2^W&58YZ>U<?_ ,+9N/\
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M4EA1110 4444 %%%% 'E?QZ_Y$>R_P"PDG_HN6OG8U]$_'K_ )$>R_["2?\
MHN6OG8UUT?A.*O\ &=+X7_U5S_O+_6N@KG_"_P#JKG_>7^M=!75'8XY[A7I7
MPE_UNK?[L7_L]>:UZ5\)?];JW^[%_P"SUG7^!FF&_B(]/HHHKSCUCRKX^?\
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M[9_^C%KEA\:.RK\#]#PZO7OA5_R+-S_U^-_Z E>0UZ]\*O\ D6;G_K\;_P!
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M +\1_P#Q-'_"P_$__01'_?B/_P")IO\ PK[Q1_T"_P#R/'_\51_PK[Q1_P!
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M7_2(Q@C_ (%3=2'<%3GV9SU%=-_PK_Q1_P! O_R/'_\ %4?\*_\ %'_0+_\
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>hrow-20201109.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaOJabP9z5Z82ekhvWB0bVmqvyEuof6OpCrjjnbGIeAP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:HROW="http://harrowinc.com/20201109" elementFormDefault="qualified" targetNamespace="http://harrowinc.com/20201109">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://harrowinc.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20201109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20201109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>hrow-20201109_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>hrow-20201109_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.5b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrowinc.com/role/Cover" xlink:href="hrow-20201109.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="loc_deiEntityInformationFormerLegalOrRegisteredName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInformationFormerLegalOrRegisteredName" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>form8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hrow-20201109.xsd" xlink:type="simple"/>
    <context id="From2020-11-08to2020-11-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <startDate>2020-11-08</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-11-08to2020-11-09">0001360214</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-11-08to2020-11-09">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2020-11-08to2020-11-09">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-11-08to2020-11-09">2020-11-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2020-11-08to2020-11-09">HARROW HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-11-08to2020-11-09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-11-08to2020-11-09">001-35814</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-11-08to2020-11-09">45-0567010</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-11-08to2020-11-09">102     Woodmont Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-11-08to2020-11-09">Suite 610</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-11-08to2020-11-09">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-11-08to2020-11-09">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-11-08to2020-11-09">37205</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-11-08to2020-11-09">(615)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-11-08to2020-11-09">733-4730</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName contextRef="From2020-11-08to2020-11-09">Not Applicable</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:Security12bTitle contextRef="From2020-11-08to2020-11-09">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-11-08to2020-11-09">HROW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-11-08to2020-11-09">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2020-11-08to2020-11-09">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2020-11-08to2020-11-09">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2020-11-08to2020-11-09">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2020-11-08to2020-11-09">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-11-08to2020-11-09">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139933947153960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  09,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HARROW
HEALTH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001360214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0567010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">102
    Woodmont Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-4730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HROW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Not
Applicable<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M^;PT-S)X:9+?W M8CI"4*K*A<<9("D/6$54H>CD3^+AU+Q0-;0O.WY*EK&S
M&H%[6,IA)*7M^[A%OV>-C%^#B(HU.[JZK!&:#N>WPY\84^GW_DE^/TZ86MLL
M?0,%$UD72:FHKB\N6-MSI=W[)[T<3,3N^T.^:+-OX] =#VP-]@L3YFZESA0+
MC^<2O\M4FK-AFH)3T67U].X<O&';KQ4_J$V5)C%;@:)[T8.$J-T'@-V.D6G^
MTKV4!E[A\\V(47B0[05P?B6E>=^Q[_'%9YC!OU!+ P04    " #1.W%1@ZFE
M ]0!   R!@  #0   'AL+W-T>6QE<RYX;6S55=N*U$ 0_96F/\">1'9!20(J
M+ @J"SL/OG:22M+0-SN5,=FOMSN=V[@,J ^B+Y,ZIZI/G;Y.UN,DX:D#0#(J
MJ?N<=HCV+6-]U8'B_2MC0?M,8YSBZ*%K66\=\+H/@Y1DZ>ETSQ07FA:9'M2#
MPIY49M"8TQ-E1=88O3.O:21\*5= +ESF] .7HG1BKN5*R"G2:2 J(XTCZ*U
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ T3MQ40=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" #1.W%1)\42K>T    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " #1.W%1F5R<(Q &  "<)P  $P
M    @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -$[<5&Z
MR(?+@@0  )(1   8              " @0P(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " #1.W%1@ZFE ]0!   R!@  #0
M    @ '$#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -$[<5&7BKL<P
M !,"   +              "  <,.  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M -$[<5&JQ"(6,P$  "("   /              "  :P/  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #1.W%1)!Z;HJT   #X 0  &@
M@ $,$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #1
M.W%199!YDAD!  #/ P  $P              @ 'Q$0  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"   [$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8k.htm">form8k.htm</File>
    <File>ex99-1.htm</File>
    <File>ex99-2.htm</File>
    <File>hrow-20201109.xsd</File>
    <File>hrow-20201109_lab.xml</File>
    <File>hrow-20201109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "form8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hrow-20201109_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hrow-20201109_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "hrow-20201109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 60,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "HROW",
   "nsuri": "http://harrowinc.com/20201109",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8k.htm",
      "contextRef": "From2020-11-08to2020-11-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://harrowinc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8k.htm",
      "contextRef": "From2020-11-08to2020-11-09",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001493152-20-021823-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-20-021823-xbrl.zip
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M'/\UN&J=1IXX?+#_4L1N'QAABCY;6;8I#>4']E1F89\@\LO0X;'UT>-O,!0
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M\@2HOI$. ;QL8#)6+]1(M5&2(/I8-27C/J1\Y'J*^M(. #>!#XX <,!@04,
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M!1&IPP?M1*R"(.9*8WFE99'/ \ 69HIY4#L#E9.105 N-6N\DAAHK+IQ= )
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M+YO%.9ZH!-6J-*WW'+/=R,N>/PG3OBR7AI)K76!\^IXY07\0F)%BYL=>'J_
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M">@!7>3806F[ZQ5\ ;8FH.U185-#\1-6.?2*Q4"HGTR:  ?^&R\MCVL+:-.
MK2536*+RQW0-[@C$>2] <)C8!0H'WF%)9J\)8?2H$@?V24$V.VNW\BG<OE'^
M:R$!3/)% LSF<-=_057&NR16+<8V2\9'A69"]>&D6VQ($U$M2FLF.O7&F8C3
MJYSMY_FLNDYT_DJU2]*@RZ6,;7,U-/K$IWRK;6 Y=G%;VK89:AQ/"EPM4!RF
M+72)PC K3OZ@%5U9EGD6VDQ[MH!R."OBB KI;9=U2-/;S?9P'5B=A:Z#<VJ2
MK9-"\9NLAN3LZ6;C.@=]J"08V^*6F:L0"ZATZ*(&!JKAO3R=9]:V39YG!FNA
M&T^<#@:!RQDJ6#;H@.J"R>4R<B8A+V*8,[UV]"XF 0 )8A<H5"^R*JN%Z]"V
ME N+$L1,;/-D=7%!G?Y:HP+! ;6P"RT_\4(^%AVQ#^H[9FU5N#7*"0#"D*@O
M)/38TZ9A 6W*9D,DHFQ'+.E*YVLM .5[]&.$GDC.!L"6885D R3;3'V?[%X]
M:Y^H+5:>/#9%F#@P&MJF!2P'&00?LZ6>*?2</QQ?PX*5\])UOI>%JW19L88,
MJ^@"D Q&<4(NQ#2T3D6Z(4^__#V3\2!^V,R0K/?-#-.)_ #LXYE/NG&>DS?&
M<)"H<OP$J-AE1/?"D$JHFR<MC;S.'NHV\#RRLXB>YOM+Q0R_;,:O\]ZJ^,#)
M?=XBT,LEM\V%3<ISF-DOJNT=1KZD1Z9 /GW!S>*NQBW<*\-7%-T(S#$L?XFQ
M.,*BEQVP?"19?Y"BEWLV%KL:R(^;=??,0=N#;=#VD8*V!]N@[=:#,BN"",*Y
M@RK*M'"(J2,C\!UL%K83F#C>M0([Z[5%ND[,F<U\6Q=XNOR"<_M8QKNMK8-7
M]C$S[F_[B;RY7)<&)68?RZW;GXS-UN9)\2I$&*M=,+,\@296H9+1#MVXWGTM
M$#*<$:$%OD[E\QR/GU0><DF7J1"HO]!LAEN:8KM?TBH6JKI?\Q3.L"S,+/T=
M@,X X#V>5O.IZ9KNZZ00%[0"F:^?3 IE++L'QQ%*OB1O;)H\)VWC.J<.%H3U
M9%_4F2H1R6UZG?0SJ["2Q-HAT:7#W?Q5S]WY1P4[*E2.DO8R-JKEA7E)3!8#
MI\I-%"KE;YADVUC&T#%H'Y!RC6<SY4.?85-/>=0]IVX3E<QQHWO3>.CA])&]
M81'1=1*J"JW(:7J+3@.^AE7SN+^K-9ASY8J-95N ]!CT;53431K#@_'NF\W"
MH)4I+,O==QZ[#3ZIR["B5;CFG:T!-8GQ:\R5H4)=!E\*_!,Q0.L_[&:Z&FEI
M+XKOYY>AWU_C6J_^]:(QN="YFI[=WO$Y9WDM/UB\N2-,^\28=C&-:0P8HMOD
MXF:N9,;\+^9LS@_NQ QM<0DU^+MQGC6[6O;13?(DN6>83O$MAU4_GG#)?OO>
M3Y=$F$T$)U@QYAYD;!KZ2'\F@N/HMG8:M7VOL7?D-9K-W1GU$"Q5-C,K8C[&
MLIU O!,[G%]:EOD16>;DNNRPC5FCSD&M\3?KR\+S<M[42XQ Z/KB],@[V#N:
M,\S2<,RFK8W:AYUZW=L_./[1G=C]8;S]HP>Z[PQDG9[K-E?B15&'9_^V'%'V
MAUO0POU>]D1G[-MQ_7#14[-&6Q4H^[6];P-EM=QE>FY7NME9.:1^K7Q7CJ?(
M^[D.Z&!:?J_L@";)Z/0.K>)5K["R+EO]C8"LAA).SPLNB)7C^<'^NFS^WO$W
M\L0G$1=G!0^0=1C)L*NY"EZL5B\J]J:DZW,=4+.Q#N2Q2%!,.=D*/K95[\[.
MH=>L+W%6NZL&Y, [J#_=22U/2=<%%^G3G$AS#4YC+43*_+D?\2+F6'S;ZFJQ
M>'O[^PV8";#/^(^Q4F9KL^DK%*_>T?X26+AB6ES*!IOPCG[5'[;8%OT^ W0Y
MHW//J^U-,;@?L+C7:&EH34]I^]^\M,D:@6OD,"9VX& =XPC6=UR(IGY. U5Q
M$=5B+'=R]9EG+^(]DFEB,N]QH_GJQ=C;UM5(3L$93MCIP8N+*+K:, 9L_RS&
M@,? 7L7F+UGU<U[(8&:$9GW0 F0%XBY^09&0<+9<L7G'F$*"32EENQVEG'-C
MZ]!0@6_,N0FT*]XM0%]/..D',U/Z ZDC4A=!K\?>)Q6L5.-;O9ZSY88:V*MO
MAJ&=9R?/9XDQ.0FCB[OXAD&#K5B<$%T64=I.N#"@K=AR&3U0Q;#WL/\=$X5:
MNK)=H]64G]J(9/?'KRIU04U+RZ4;,-XZ0-=F%?6EMH&TL4#:DN**PRS+1'QL
MIL?J(W./!O%52N$<(/9;[!1/&2;ON0$AN9W7. ZW_"(?_1[&5'VS^B-?:GEW
M>@%BKD_\^3\R2)60R42436SBJJ;S"C8E=GCP:I8.>Y$ H4Q5Z9X3'ELZ%O:-
M@;?ZT:LY5D>S5O-JM2GU_/NG^J%%S(O>S8._<>@=-']L 4\3G[/=P0O=ZE?N
M8IUWM(_L-I@ZLED68-UK\C'5U]ES-%?F4I/<K]#PMXBMQ9)RV4-?XO6OX<(J
M(%B\YJ\G#"V!8M\VB$/"0[<+4TCX7=NP L;AX,#)@)/69NI-,X5,I@K<&;R;
M1 K!JCG,UQ_<$ =5\\ [G$T?/Y.7:K8UMG5-3;5M&5OB1)J=7?&,O+M_AD]K
M'(G0GU5WCJW/RMX+CHLYR'@=5[G+PWKL*IET?6-#X)Q42'X0X9U\>ST+0<"K
M$.*&KN!C/CW9FV(GN_F%"<UXMZ[-_JZ.<FXINJDWH"YH&-2V-85W13\-$@U?
MYY?0PLRZC:UU2SWY6JX"='7MO"J+KKDOOL%U> (**%U;>",^8O.Z[86NQ[G0
M=?A#%[K6_J[5PL(*K]]=G_^79-YO=Y\^GOY_4$L#!!0    ( -$[<5%J,+AC
MNQ,  %V3   *    9F]R;3AK+FAT;>T]:U?:S-;?7<O_,"_G/&?9=>02;@I:
MSD)$I5ZP8*OM%]<D&6 D)&DR$>BO?_=,$B"06)30HK5]G@+)7/;L^]ZS,SG\
MWVB@H4=BV=30/R:D5":!B*X8*M6['Q,.ZR3W$_^K;&\=]ABT@[:Z_3'18\PL
MI]/#X3 US*4,JYN62J52>L3;)-Q&Y5%HNVPF(Z7O+B_:2H\,<)+J-L.Z0B:=
M-*KWH\?G=R=-94NC@:;\BC])+KTP--Q5IQUF&Q?3[LU 4Q;:M. V97Y3:AOY
MK+3W%!QNBTF'451;B<,,*R1W1ZV+:7,6WG[:-,TLK-L=PQI@!C3D(Q62F6PR
M6YP9)&D3)3 0_$YUC<=?CK.?S$G^. O$":Z4WY:Q/<&X2N;0[<\)-Z!'-I/,
M2#.C6Z03.7@Q#7?]AHZ=[&)L3AIWL"V+AMZ-D+'ACF5HQ [M(^Z$=%(,1V?6
M.'P-WLV0;K;%%J>!BR%-SUK-VTG;'K8L8TAU):48 ]%8DC*EA) ]@E7X1/S/
M(:-,(Y7#M/L)=P>$8<0'29(?#GW\F*@9.B,Z2]Z,32"&XO[ZF&!DQ-*NB*9Y
MO[0W[.'_)9/HA!)-+:,V80?H"@](&8W4T0%J'(LO]YELZ?Y+^Y_L\6FU>@T?
M'#R43"[;.U>]YVN]#ZSQWE_C,P;*2WZO_9=T+QS=$^ ^6 #\5]<!A>,:X,;"
M6D-7R>B<C.\SH*%RQ4Q6RC]GW-+,N-4!T57XGYUHN'O?P9I-GC%4\0@0?7PO
MW7N*PQT3+CUGC.Q]&U!-[/OLO="3[B"VN/:<<8XY+-?>6+D%D"('EPUUC&PV
MULC'1 ?XKXRDC,G0#1U DRLR1"UC@/5=]\(N &#1CN!TE3[Z_51JFQH>EY%N
MZ$3<I*,R9UEB"5D0/ZFJ$MT3#7X!VEXY QA.<?E^Q%I<K9Q8QD"(GR2!2F/&
MY'LI@718.,Q&:#F4(1*5*4<<I@-3K#:OJVD_)D [EV4#=!#6!:_,0A1@I41%
MW(\ (AU$!P<*=":QP)@3VV_$5739%K87X$/"H)9[KN8%P4SZ(I4:V6K"N\U
MBWQ,V'1@:L35')/YYB9PY[0-QYJ94K!(V4,*HNJ32/&5G-^-"(I,KDZN4Y7?
MZ5!B(;$:$FK;:HWS(/7F.T^G2X?.Y\UF IX-=1$*<# L=HP9J4R7XX\TO;?0
M#4@:[%2:3J\&NOC7 P#X%SV4!O'LZ-1%,DCG C8'!-N.12J>&)>AC3^8?RLX
M!1\M8GQ7)T1.X2%!-'KQ'%/=LS /Z D@XR)N>5\A&)@9ULSMY^-@'L:P46<F
M/2:Z,:#ZKZ;]-5[FYPT;V+\?P$(80M,+$NGJ"5^+'J9A"/CD?P_-YVKL S3
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MO\L=?5=NOL(KDHZ05 HZP':=-.HJ@R:NS=X2GK#X@G[,M1GMR;[XV^'Y_]"
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MP&ZRR4)3$Q /5F, $WMM\>2J1R[F8JSB.%W0F.Q^(6]@ZUHZMV0 -IMH&**
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M.ZVB2T.;\X667S27PL:")-7%FJ:\\NZ\UR!XX:WHL-0)D]HZ8Y0[PO*QX/%
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M4$L! A0#%     @ T3MQ4=8:./3K*0  *!@!  H              ( !A@P
M &5X.3DM,BYH=&U02P$"% ,4    " #1.W%1:C"X8[L3  !=DP  "@
M        @ &9-@  9F]R;3AK+FAT;5!+ 0(4 Q0    ( -$[<5$HNK6@0 ,
M )(,   1              "  7Q*  !H<F]W+3(P,C Q,3 Y+GAS9%!+ 0(4
M Q0    ( -$[<5%)^>'X-PL  (R*   5              "  >M-  !H<F]W
M+3(P,C Q,3 Y7VQA8BYX;6Q02P$"% ,4    " #1.W%1@M<X)'4'  #L6@
M%0              @ %560  :')O=RTR,#(P,3$P.5]P<F4N>&UL4$L%!@
0   &  8 ;0$  /U@      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
